Intellia Therapeutics Stock And 2 High Growth Shares With Strong Balance Sheets

With inflation, energy costs and interest rates all under close watch, many investors are looking for companies that pair solid balance sheets with the prospect of faster earnings growth. That is exactly what the Healthy high growth potential screener targets. It focuses on stocks that analysts expect to deliver stronger earnings over the next 3 years while still meeting basic financial health checks. In this article, you will see 3 of the most interesting stocks from this screener and how each one fits into the current mix of inflation worries, central bank decisions and shifting global trade and labour trends.

Intellia Therapeutics (NTLA)

Overview: Intellia Therapeutics is a clinical-stage biotech company that uses CRISPR/Cas9 gene editing to develop potentially curative treatments for inherited and immune-related diseases, including transthyretin amyloidosis and hereditary angioedema, through both in vivo and ex vivo therapies and a network of development partnerships.

Operations: Intellia currently generates about US$66.1 million in revenue from the development of gene editing based therapies, all reported from the United States.

Market Cap: US$1.6b

Intellia Therapeutics is drawing attention because it sits at the center of CRISPR-based treatments that could offer one-time, potentially curative options for conditions like hereditary angioedema, backed by Phase 3 data and a rolling U.S. biologics filing in progress. At the same time, the company is still reporting sizeable losses and depends on external funding, so dilution and cash burn are front of mind for many investors. The share price has been volatile and has lagged the broader market. Some analysts see strong revenue and earnings growth potential if multiple programs reach commercialization. The key issue for investors is how promising clinical milestones, funding decisions and rising competition in gene editing might reshape the overall risk and reward profile.

Intellia Therapeutics sits at the crossroads of high stakes gene editing and rising competition, and the real tension is how that story meets its funding needs and cash burn profile in the Intellia Therapeutics financial health report

Insulet (PODD)

Overview: Insulet develops and sells the Omnipod family of wearable insulin delivery systems, which automate insulin dosing for people with diabetes by integrating pods worn on the body with continuous glucose monitors and app based controllers, and it also supplies drug delivery pods for partners such as Amgen.

Operations: Insulet generates about US$2.9b in revenue from drug delivery systems, with roughly US$2.1b from the United States and US$844.9m from international markets.

Market Cap: US$11.4b

Insulet is on many investors’ radar because Omnipod 5 sits at the heart of a growing, recurring revenue stream as more people with type 1 and type 2 diabetes adopt wearable, app connected insulin delivery. New data on Omnipod 6 and fully closed loop systems points to a deeper product pipeline. At the same time, dependence on a single platform, recent global product recalls and lawsuits over manufacturing controls underline that execution risk is real, especially with a premium P/E and reliance on external borrowing. For investors tracking the Healthy high growth potential screener, the key question is how that mix of high forecast earnings growth, strong ROE and concentrated product risk fits their view of quality growth at a reasonable price.

Insulet’s fast growing Omnipod platform and premium P/E often get attention, but fewer investors examine how earnings expectations compare with concentrated product and recall risk in the analyst forecasts for Insulet

Hamilton Lane (HLNE)

Overview: Hamilton Lane is a Philadelphia based private equity and venture capital firm that manages a wide range of alternative investment strategies, from buyouts and credit to infrastructure and evergreen funds, for institutional and high net worth clients around the world.

Operations: Hamilton Lane generates about US$759.0 million in revenue from asset management, with roughly US$310.4 million from the United States and US$448.6 million from other countries.

Market Cap: US$4.8b

Hamilton Lane is attracting interest because it sits at the center of demand for private markets access, with fee earning assets tied to evergreen and specialized funds, a 32.8% net margin and a 26.4% ROE that many investors associate with quality asset managers. At the same time, the business is exposed to fee pressure, heavier regulation and funding risk given its reliance on external borrowing. Its latest quarter showed a 2.2% revenue decline and an earnings miss that pulled the stock back. For investors using the Healthy high growth potential screener, the key point is how that combination of forecast double digit earnings growth, a discount to some fair value estimates and rising competition in alternatives might reshape Hamilton Lane’s risk and opportunity over the next few years.

Hamilton Lane’s high ROE and net margin suggest a stronger story than a single soft quarter, but the real question is how that holds up across private markets cycles in the 4 key rewards and 1 important warning sign

The three stocks covered here are only a starting point, with the full Healthy high growth potential screen surfacing 255 more companies that pair strong forecast earnings growth with balance sheets that clear key quality checks in the Healthy high growth potential screener. Use Simply Wall St to identify and analyze the specific catalysts, funding profiles and earnings narratives that matter most to you, so you can focus on the highest conviction opportunities.

Take Control of Your Investment Journey

If Insulet or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

Some of the most interesting breakouts start quietly. Then momentum builds and the best entry points vanish. Scan fresh stock ideas while it matters and get in early.

• Spot under the radar strength in companies with resilient cash flows and robust balance sheets using the curated list of solid balance sheet and fundamentals (48 results)
• Ride structural shifts in automation and productivity by tracking hand picked businesses in the 32 robotics and automation stocks as adoption spreads and old models start dropping behind.
• Position ahead of potential copper supply squeezes with a focused group of producers in the 8 top copper producer stocks before broader market attention catches up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com